Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 24

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 24
---
onged approach
utilizing Virtual Sales Representatives (VSRs), a programmatic email campaign, and a co-pay offering for commercially insured patients.
We do not initially plan to target U.S. government agencies as these organizations are either contracting their ex-U.S footprints or,
as in the case of the Department of Defense, are expected to be extremely price sensitive until operational considerations justify the
use of superior products – for example, the DOD used inexpensive doxycycline for malaria prevention in the low malaria risk setting
of Afghanistan, but chose superior weekly mefloquine, despite safety concerns, for the Ebola mission to west Africa in 2014, where malaria
rates were extremely high.

Digital Revamp and Collateral: Our marketing
strategy and objectives for the promotional pilot include marketing assets that we believe best highlight the features and benefits of
Arakoda, namely the convenience of the travel and post-travel regimen, and global effectiveness and a co-pay benefit to reduce the out-of-pocket
expense for individuals with commercial insurance. All marketing assets will reside on ARAKODA.com including a convenient dosing card,
access to the co-pay offer, and information on how to get ARAKODA.

Revised Forecast. We have developed an internal
forecast for the malaria and indication and will do the same for the Babesiosis indication after completion of market research studies.

Development of the Arakoda Regimen of Tafenoquine for Babesiosis

In animal models, Tafenoquine monotherapy has been
shown to suppress acute babesiosis infections to the point where the immune system can control them following single or multiple doses
similar to those effective against malaria parasites, and longer regimens alone or in combination with atovaquone leads to complete radical
cure and to the conference of sterile immunity.33 In three case studies in individuals with immunosuppression and/or refractory
parasites, Tafenoquine alone or in combination with various standard of care antimalarials and antibiotics successfully cleared parasites,
leading to three consecutive negative PCR tests, and prevention of further relapses in two of three individuals.34 Our market
research has revealed that recent sales growth for Arakoda is primarily attributable to organic growth in prescribing by Lyme community
prescribers for Chronic Babesiosis. Collectively these data suggest Tafenoquine might have utility alone or in combination as treatment
or post-exposure prophylaxis of babesiosis (both acute and chronic).

The Company is planning